- •Weight loss is proportional to the risk of death among mCRC patients.
- •Weight loss ≥5% is associated with significantly shorter survival.
- •Median overall survival was 20.5 months if there was no weight loss.
- •Median overall survival was 11.9 months if ≥ 5% weight loss at 3 months.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- NCCN Guidelines: Colon cancer. vol. 3. 2021ed2021
- Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases.JCO Precis Oncol. 2021; 5
- Circulating mutant DNA to assess tumor dynamics.Nat Med. 2008; 14: 985-990
- Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.Cancer. 2013; 119: 1528-1536
- Body mass index and weight loss in metastatic colorectal cancer in CALGB (alliance)/SWOG 80405.JNCI Cancer Spectr. 2020; 4 (pkaa024)
- Clinical evaluation and pattern of symptoms in colorectal cancer patients.Arq Gastroenterol. 2020; 57: 131-136
- Association of weight change after colorectal cancer diagnosis and outcomes in the kaiser permanente northern California population.Cancer Epidemiol Biomarkers Prev. 2017; 26: 30-37
- Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database.J Clin Oncol. 2016; 34: 144-150
- A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab.Med Oncol. 2012; 29: 1005-1009
- Body mass index and long-term outcomes in patients with colorectal cancer.Front Oncol. 2018; 8: 620
- Impact of weight changes after the diagnosis of stage III colon cancer on survival outcomes.Clin Colorectal Cancer. 2016; 15: 16-23
- Long-term weight loss after colorectal cancer diagnosis is associated with lower survival: the Colon Cancer Family Registry.Cancer. 2017; 123: 4701-4708
- Prognostic significance of unintentional body weight loss in colon cancer patients.Mol Clin Oncol. 2018; 8: 533-538
- Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: an Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database.J Clin Oncol. 2017; 35: 1929-1937
- Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.Cancer. 2013; 119: 2564-2573
- Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.J Clin Oncol. 2013; 31: 1539-1547
- Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients.Am J Clin Nutr. 2019; 110: 1395-1403
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med. 2004; 350: 2335-2342
- Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.J Clin Oncol. 2005; 23: 3706-3712
- Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N Engl J Med. 2009; 360: 1408-1417
- A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol. 2004; 22: 23-30
- Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol. 2009; 27: 663-671
- The ARCAD advanced colorectal cancer database--open for business.Ann Oncol. 2012; 23: 281-282
- Definition and classification of cancer cachexia: an international consensus.Lancet Oncol. 2011; 12: 489-495
- Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy.Br J Nutr. 2013; 109: 894-897
- Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.Ann Oncol. 2002; 13: 308-317
- Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).Int J Cancer. 2022; 150: 112-123
- Association of cancer screening deficit in the United States with the COVID-19 pandemic.JAMA Oncol. 2021; 7: 878-884
- Association of long-term trajectories of neighborhood socioeconomic status with weight change in older adults.JAMA Netw Open. 2021; 4e2036809
- Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer.J Clin Oncol. 2016; 34: 1339-1344
- Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?.Am J Clin Nutr. 2013; 98: 1012-1019
- Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.J Clin Oncol. 2005; 23: 9441-9442
- No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.BMC Cancer. 2019; 19: 847
- A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands.Am J Clin Nutr. 2009; 89: 1173-1179
- The concept of “Obstruction-Free Survival” as an outcome measure in advanced colorectal cancer management.Pleura Peritoneum. 2018; 320180101
- Body weight and composition changes, primary tumor side, and resection as survival predictors in metastatic colorectal cancer.J Clin Oncol. 2018; 36: 950
- Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer.Ann Surg Oncol. 2001; 8: 632-637
- Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.Cancer. 2000; 88: 358-363
- ESPEN expert group recommendations for action against cancer-related malnutrition.Clin Nutr. 2017; 36: 1187-1196
- ESPEN practical guideline: clinical Nutrition in cancer.Clin Nutr. 2021; 40: 2898-2913
- Cancer cachexia: identification by clinical assessment versus international consensus criteria in patients with metastatic colorectal cancer.Nutr Cancer. 2018; 70: 1322-1329
☆☆Presented in part at 2022 ASCO Gastrointestinal Cancers Symposium.